GlassScriptPhysician profile
Vivian L Marks
NPI 1225467806
$868.61
in general payments reported to CMS, 2019-2025
20 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.56 · 2022: $182 · 2023: $247 · 2024: $179 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $122.34 | 2022-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Supernus Pharmaceuticals, INC. | $120.30 | 2024 | Qelbree |
| Corium, LLC | $99.65 | 2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $91.64 | 2025 | Jornay Pm |
| Novo Nordisk INC | $58.70 | 2022-2024 | |
| Seqirus USA INC | $48.51 | 2024-2025 | Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.63 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $42.67 | 2022-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $41.56 | 2021 | |
| Acadia Pharmaceuticals INC | $26.51 | 2025 | Daybue |
| Pfizer INC. | $22.68 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.08 | 2022 | |
| Neurelis, INC. | $17.90 | 2023 | Valtoco |
| Lilly USA, LLC | $16.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.26 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.84 | 2022 | |
| Dexcom, INC. | $15.80 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2025 | Zoryve |
| Indivior INC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.